(Q80286608)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Matthew G Fury

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Andrew Zahalsky

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Richard Wong

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Ennapadam Venkatraman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Eric Lis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Lucy Hann

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Timothy Aliff

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

William Gerald

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Martin Fleisher

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

David G Pfister

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

16 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

30 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

165-172

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16983506%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-006-9011-x

30 December 2019

exact match

0 references

cites work

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

1 reference

12 December 2020

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Lymphadenopathy: differentiation of benign from malignant disease--color Doppler US assessment of intranodal angioarchitecture.

1 reference

12 December 2020

Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma

1 reference

12 December 2020

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

12 December 2020

Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.

1 reference

12 December 2020

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types

1 reference

12 December 2020

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis

1 reference

12 December 2020

Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling.

1 reference

12 December 2020

Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations

1 reference

12 December 2020

A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.

1 reference

12 December 2020

Two-dimensional and three-dimensional power Doppler sonographic classification of vascular patterns in cervical lymphadenopathies.

1 reference

12 December 2020

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells

1 reference

12 December 2020

SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells

1 reference

12 December 2020

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

1 reference

12 December 2020

Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.

1 reference

12 December 2020

A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer

1 reference

12 December 2020

Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas

1 reference

12 December 2020